RECRUITING

Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.

Official Title

Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)

Quick Facts

Study Start:2024-07-10

Study Completion:2037-12-28

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06377527

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Adult patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA). 2. Patients can also be diagnosed with mesonephric adenocarcinoma (MA) or patients with mesonephric and mesonephric-like carcinosarcomas. 3. Patients who are receiving or have received treatment at any facility, including but not limited to MD Anderson Cancer Center are eligible. 4. Patients may be residents of any country and be of any ethnic background. 5. Patients who request to participate in the registry, regardless of the method by which they learned of it, are eligible to participate. 6. Patients who do not speak English can be eligible if accompanied by an institutional interpreter.	1. Patients with other subtypes of EACs.

Inclusion Criteria

Exclusion Criteria

1. Adult patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA).
2. Patients can also be diagnosed with mesonephric adenocarcinoma (MA) or patients with mesonephric and mesonephric-like carcinosarcomas.
3. Patients who are receiving or have received treatment at any facility, including but not limited to MD Anderson Cancer Center are eligible.
4. Patients may be residents of any country and be of any ethnic background.
5. Patients who request to participate in the registry, regardless of the method by which they learned of it, are eligible to participate.
6. Patients who do not speak English can be eligible if accompanied by an institutional interpreter.

1. Patients with other subtypes of EACs.

Contacts and Locations

Study Contact

Jeffrey How, MD

CONTACT

877-632-6789

askmdanderson@mdanderson.org

Principal Investigator

Jeffrey How, MD

PRINCIPAL_INVESTIGATOR

M.D. Anderson Cancer Center

Study Locations (Sites)

MD Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Jeffrey How, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-07-10

Study Completion Date2037-12-28

Study Record Updates

Study Start Date2024-07-10

Study Completion Date2037-12-28

Terms related to this study

Additional Relevant MeSH Terms

Mesonephric-like Adenocarcinoma